Mohammed Osman Mirza

Analysis of drug development risks for metabolic dysfunction-associated steatotic liver disease from a sustainable accounting perspective

Abstract Background Metabolic dysfunction-associated steatotic liver disease (MASLD) is among the most common chronic liver diseases worldwide [1], and its targeted therapy and new drug development have drawn extensive global attention. Prior relevant studies mainly focus on the...